InflaRx (IFRX) Research & Development (2016 - 2026)
InflaRx (IFRX) recorded Research & Development of $3.49 million in Q3 2026, down 52.1% from $7.3 million a year earlier and down 36.6% from the prior quarter.
Powered by 
Analysis
InflaRx (IFRX) Research & Development (2016 - 2026) Analysis & Trends
On a TTM basis, InflaRx's Research & Development came in at $20.01 million as of Sep 30, 2026, down 33.8% year-over-year; for FY2025, it was $29.06 million, down 24.1% from FY2024.
- Annual Research & Development has a five-year compound annual growth rate of -0.2% (FY2020 to FY2025).
- Across earlier years, Research & Development came in at $38.28 million in FY2024 (-13.7%), $44.38 million in FY2023 (+12.2%), $39.55 million in FY2022 (-6.4%) and $42.24 million in FY2021 (+44.1%).
- The Q3 2026 figure is the lowest quarterly Research & Development since Q4 2019.
- On a year-over-year basis, Research & Development has declined for eight consecutive quarters, with an average decline of 27.8% over the last eight quarters.
- Peak year-over-year performance for Research & Development in the last five years was growth of 98.6% in Q1 2022, against a decline of 52.1% in Q3 2026 at the low end.
- Per Business Quant, the preceding three quarters came in at $5.51 million (Q2 2026), $4.88 million (Q1 2026) and $6.12 million (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn | 4.25 Bn |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn | 2.57 Bn |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn | 4.54 Bn |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn | 2.11 Bn |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn | 1.61 Bn |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn | 3.02 Bn |
| 10 | InflaRx | 85.79 Mn | -160.38 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 3.49 Mn |
| Jun 30, 2026 | 5.51 Mn |
| Mar 31, 2026 | 4.88 Mn |
| Dec 31, 2025 | 6.12 Mn |
| Sep 30, 2025 | 7.30 Mn |
| Jun 30, 2025 | 8.15 Mn |
| Mar 31, 2025 | 7.38 Mn |
| Dec 31, 2024 | 7.38 Mn |
| Sep 30, 2024 | 12.23 Mn |
| Jun 30, 2024 | 10.79 Mn |
| Mar 31, 2024 | 7.93 Mn |
| Dec 31, 2023 | 8.68 Mn |
| Sep 30, 2023 | 7.95 Mn |
| Jun 30, 2023 | 11.89 Mn |
| Mar 31, 2023 | 15.81 Mn |
| Dec 31, 2022 | 8.50 Mn |
| Sep 30, 2022 | 7.60 Mn |
| Jun 30, 2022 | 11.93 Mn |
| Mar 31, 2022 | 11.75 Mn |
| Dec 31, 2021 | 11.59 Mn |
API Access
InflaRx Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=IFRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "IFRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=IFRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();